Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
MARA Marathon Patent Group Inc
HNGR Hanger Inc
$RFTREES Refinitiv Eurozone ESG Select Index
NEMCF New Energy Metals Corp
SLCT Select Bancorp Inc
HPQ HP Inc
GOLD Barrick Gold Corp
DGNR Dragoneer Growth Opportunities Corp
EQMEF Equity Metals Corp
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Price
Delayed
$534.80
Day's Change
0.913 (0.17%)
Bid
--
Ask
--
B/A Size
--
Day's High
543.99
Day's Low
529.31
Volume
(Light)

Today's volume of 362,710 shares is on pace to be much lighter than REGN's 10-day average volume of 1,073,315 shares.

362,710

Display:

Providers:

UpdateCancel
4 providers
January 12, 2021
Regeneron says U.S. government to buy 1.25 million doses of its COVID-19 treatment

Regeneron Pharmaceuticals Inc. (REGN) said late Tuesday that the U.S. government has agreed to buy an additional 1.25 million doses of the company's COVID-19 antibody cocktail. That would bring the U.S. supply of the cocktail, consisting of...(MarketWatch)

December 30, 2020
Regeneron says it will continue trial of COVID antibody cocktail as latest data show positive results

Regeneron Pharmaceuticals Inc. (REGN) said initial data from its Phase 1/2/3 clinical trial of its antibody cocktail in hospitalized COVID-19 patients requiring low-flow oxygen passed a futility analysis, meaning there was sufficient efficacy...(MarketWatch)

November 25, 2020
Equillium's stock tumbles after decision to not initiate late-stage trial of COVID-19 treatment

Shares of Equillium Inc. (EQ) tumbled 12.6% in premarket trading Wednesday, after the biotechnology company said it decided not to initiate a Phase 3 trial its itolizumab for the treatment of hospitalized COVID-19 patients "at this time." The...(MarketWatch)

November 23, 2020
UPDATE: U.S. coronavirus case tally tops 12 million amid growing fears that Thanksgiving travel will spark another surge of infections

By Ciara Linnane, MarketWatch 'Four days before a holiday with potentially the most indoor and in-person gatherings of the year in the U.S., the virus is here and more prevalent than ever,' says one analyst (MarketWatch)

November 06, 2020
UPDATE: Regeneron blows past third-quarter earnings estimates and says has shared COVID-19 data with FDA

Regeneron Pharmaceuticals Inc. shares (REGN) rose 1.6% in premarket trade Thursday, after the drug company blew past estimates for the third quarter and said it has shared data from its Phase 2/3 COVID-19 antibody therapy trial with regulators...(MarketWatch)

November 05, 2020
Regeneron shares up 1.8% premarket

(END) Dow Jones Newswires November 05, 2020 06:36 ET (11:36 GMT) Copyright (c) 2020 Dow Jones & Company, Inc.(MarketWatch)

Regeneron Q3 adj. EPS $8.36; FactSet consensus $6.97

(END) Dow Jones Newswires November 05, 2020 06:34 ET (11:34 GMT) Copyright (c) 2020 Dow Jones & Company, Inc.(MarketWatch)

Regeneron Q3 revenue $2.294 bln vs. $1.744 bln; FactSet consensus $2.082 bln

(END) Dow Jones Newswires November 05, 2020 06:34 ET (11:34 GMT) Copyright (c) 2020 Dow Jones & Company, Inc.(MarketWatch)

Regeneron Q3 EPS $7.39 vs. $5.86

(END) Dow Jones Newswires November 05, 2020 06:33 ET (11:33 GMT) Copyright (c) 2020 Dow Jones & Company, Inc.(MarketWatch)

October 30, 2020
Regeneron says IDMC recommends halt of some REGN-COV2 trial enrollment for safety risks

Shares of Regeneron Pharmaceuticals Inc. (REGN) slumped 1.2% in morning trading Friday, after the biotechnology company said an independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19...(MarketWatch)

Regeneron: IDMC recommends enrollment of some COVID-19 treatment trial placed on hold

(END) Dow Jones Newswires October 30, 2020 09:20 ET (13:20 GMT) Copyright (c) 2020 Dow Jones & Company, Inc.(MarketWatch)

October 29, 2020
Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.(Zacks)

October 28, 2020
Regeneron: Trial COVID-19 drug cocktail cut virus load in more people

Shares of Regeneron Pharmaceuticals Inc. (REGN) rose more than 3% in the extended session Wednesday after the company said its experimental antibody cocktail "significantly reduced" novel-coronavirus levels and the need for "further medical...(MarketWatch)

October 14, 2020
UPDATE: Regeneron gets FDA approval for Ebola drug

Regeneron Pharmaceuticals Inc. (REGN) said late Wednesday the Food and Drug Administration approved its treatment for the Ebola virus. The biotech company said the agency approved Inmazeb, the first FDA-approved treatment for Ebola. In a...(MarketWatch)

Regeneron gets FDA approval for Ebola drug

Regeneron Pharmaceuticals Inc. (REGN) said late Wednesday the Food and Drug Administration approved its treatment for the Ebola virus. The biotech company said the agency approved Inmazeb, the first FDA-approved treatment for Ebola. In a...(MarketWatch)

October 13, 2020
UPDATE: A study testing Lilly's antibody treatment and remdesivir is paused

Shares of Eli Lilly & Co. (LLY) tumbled 3.1% in trading on Tuesday after the drug maker confirmed a data safety monitoring board had paused enrollment in a clinical study testing its experimental COVID-19 monoclonal antibody treatment in...(MarketWatch)

October 11, 2020
UPDATE: Regeneron CEO cautions Trump's results are 'a case of one,' and coronavirus drug needs more testing

By Mike Murphy Leonard Schleifer tells CBS News that immunity through drug cocktail should last months, at least President Donald Trump has called the antibody cocktail he received to fend off the coronavirus "a cure...(MarketWatch)

Regeneron CEO cautions Trump's results are 'a case of one,' and coronavirus drug needs more testing

By Mike Murphy Leonard Schleifer tells CBS News that immunity through drug cocktail should last months, at least President Donald Trump has called the antibody cocktail he received to fend off the coronavirus "a cure...(MarketWatch)

October 08, 2020
Regeneron's stock rallies after it announces EUA request for antibody treatment

Shares of Regeneron Pharmaceuticals Inc. (REGN) were up 4.7% in premarket trading on Thursday, the day after the company said it had submitted a request for emergency authorization to the Food and Drug Administration for its experimental antibody...(MarketWatch)

UPDATE: Trump calls contracting coronavirus 'blessing from God' in latest video

By Robert Schroeder, MarketWatch President talks up Regeneron 'cocktail,' and stock rises in after-hours trading President Donald Trump said that contracting the coronavirus was a "blessing from God" in a new video released Wednesday, as he...(MarketWatch)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.